Hematologic Malignancy
Monoclonal Immunoglobulin Deposition Disease
CI-CAN-00006049Explore in graph →
HematologicNon-malignant37 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006049Explore in graph →
Clinical trials
148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01728259 | First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | terminated | Phase 1 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 2 | May 9, 2023 | clinicaltrials |
| NCT04115956 | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | terminated | Phase 1 | 6 | Oncopeptides ABINDUSTRY | 9 | Mar 28, 2022 | clinicaltrials |
| NCT03000660 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis | terminated | Phase 1 | 3 | Tufts Medical CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | terminated | Phase 1 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Sep 23, 2019 | clinicaltrials |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated May 9, 2023source: clinicaltrials